Literature DB >> 15234435

Incidence and follow-up of inflammatory cardiac complications after smallpox vaccination.

Robert E Eckart1, Suzanne S Love, J Edwin Atwood, Mark K Arness, Dimitri C Cassimatis, Charles L Campbell, Sheri Y Boyd, Joseph G Murphy, David L Swerdlow, Limone C Collins, James R Riddle, David N Tornberg, John D Grabenstein, Renata J M Engler.   

Abstract

OBJECTIVES: The purpose of this study was to assess the follow-up of patients with vaccinia-associated myocarditis.
BACKGROUND: With the threat of biological warfare, the U.S. Department of Defense resumed a program for widespread smallpox vaccinations on December 13, 2002. One-year afterwards, there has been a significant increase in the occurrence of myocarditis and pericarditis among those vaccinated.
METHODS: Cases were identified through sentinel reporting to military headquarters, systematic surveillance, and spontaneous reports.
RESULTS: A total of 540,824 military personnel were vaccinated with a New York City Board of Health strain of vaccinia from December 2002 through December 2003. Of these, 67 developed myopericarditis at 10.4 +/- 3.6 days after vaccination. The ST-segment elevation was noted in 57%, mean troponin on admission was 11.3+/- 22.7 ng/dl, and peak cardiac enzymes were noted within 8 h of presentation. On follow-up of 64 patients (96%) at a mean of 32 +/- 16 weeks, all patients had objective normalization of echocardiography, electrocardiography, laboratory testing, graded exercise testing, and functional status; 8 (13%) reported atypical, non-limiting persistent chest discomfort.
CONCLUSIONS: Post-vaccinial myopericarditis should be considered in patients with chest pain within 30 days after smallpox vaccination. Normalization of echocardiography, electrocardiography, and treadmill testing is expected, and nearly all patients have resolution of chest pain on follow-up.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15234435     DOI: 10.1016/j.jacc.2004.05.004

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  54 in total

1.  Bioterrorism and compulsory vaccination: United States continues vaccinating to keep troops healthy.

Authors:  John D Grabenstein; William Winkenwerder
Journal:  BMJ       Date:  2004-10-23

2.  The poxvirus A35 protein is an immunoregulator.

Authors:  Kristina E Rehm; Gwendolyn J B Jones; Alice A Tripp; Mark W Metcalf; Rachel L Roper
Journal:  J Virol       Date:  2010-01       Impact factor: 5.103

3.  Ischemic cardiac events and other adverse events following ACAM2000(®) smallpox vaccine in the Vaccine Adverse Event Reporting System.

Authors:  Michael M McNeil; Maria Cano; Elaine R Miller; Brett W Petersen; Renata J M Engler; Marthe G Bryant-Genevier
Journal:  Vaccine       Date:  2014-06-18       Impact factor: 3.641

4.  Vaccination and risk of lone atrial fibrillation in the active component United States military.

Authors:  Michael M McNeil; Susan K Duderstadt; Jennifer F Sabatier; Gina G Ma; Jonathan Duffy
Journal:  Hum Vaccin Immunother       Date:  2019-01-08       Impact factor: 3.452

5.  Assessment of edema using STIR+ via 3D cardiovascular magnetic resonance imaging in patients with suspected myocarditis.

Authors:  Michael Jeserich; Bela Merkely; Pascal Schlosser; Simone Kimmel; Gabor Pavlik; Stephan Achenbach
Journal:  MAGMA       Date:  2017-01-16       Impact factor: 2.310

6.  Safety, immunogenicity, and surrogate markers of clinical efficacy for modified vaccinia Ankara as a smallpox vaccine in HIV-infected subjects.

Authors:  Richard N Greenberg; Edgar Turner Overton; David W Haas; Ian Frank; Mitchell Goldman; Alfred von Krempelhuber; Garth Virgin; Nicole Bädeker; Jens Vollmar; Paul Chaplin
Journal:  J Infect Dis       Date:  2012-12-07       Impact factor: 5.226

7.  Vaccinia virus A35R inhibits MHC class II antigen presentation.

Authors:  Kristina E Rehm; Ramsey F Connor; Gwendolyn J B Jones; Kenneth Yimbu; Rachel L Roper
Journal:  Virology       Date:  2009-12-02       Impact factor: 3.616

8.  A randomized, double-blind, dose-finding Phase II study to evaluate immunogenicity and safety of the third generation smallpox vaccine candidate IMVAMUNE.

Authors:  Alfred von Krempelhuber; Jens Vollmar; Rolf Pokorny; Petra Rapp; Niels Wulff; Barbara Petzold; Amanda Handley; Lyn Mateo; Henriette Siersbol; Herwig Kollaritsch; Paul Chaplin
Journal:  Vaccine       Date:  2009-11-25       Impact factor: 3.641

Review 9.  Non-invasive imaging in the diagnosis of acute viral myocarditis.

Authors:  Michael Jeserich; Stavros Konstantinides; Gabor Pavlik; Christoph Bode; Annette Geibel
Journal:  Clin Res Cardiol       Date:  2009-09-11       Impact factor: 5.460

10.  Cardiac complication after experimental human malaria infection: a case report.

Authors:  An-Emmie Nieman; Quirijn de Mast; Meta Roestenberg; Jorien Wiersma; Gheorghe Pop; Anton Stalenhoef; Pierre Druilhe; Robert Sauerwein; André van der Ven
Journal:  Malar J       Date:  2009-12-03       Impact factor: 2.979

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.